Evidence map›Paper›PMID 39301091›Full record

ArticleJournal of psoriasis and psoriatic arthritis2024

Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study.

Christopher Willy Schwarz, Lone Skov, Alexander Egeberg, Alun Passey, Jennifer Lee, Patricia Gorecki, Nikolai Loft

Abstract read
In one paragraph

Article in Journal of psoriasis and psoriatic arthritis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Oral Roflumilast in Patients with Psoriasis: A Real-World Cohort Study.American journal of clinical dermatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher Willy SchwarzDepartment of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-2255-398X
Lone SkovDepartment of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4784-9680
Alexander EgebergDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Alun PasseyJanssen Pharmaceutica N.V., Beerse, Belgium.
Jennifer LeeJanssen Pharmaceutica N.V., Beerse, Belgium.
Patricia GoreckiJanssen, High Wycombe, UK.ORCID https://orcid.org/0000-0002-5657-5001
Nikolai LoftDepartment of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-2950-3280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psoriasis is associated with several comorbidities and patients with psoriasis are more often obese than individuals without psoriasis. The excess disease burden is important to consider in choice of and response to treatment at the individual level. Objective: To investigate whether patient characteristics differ across biologics for patients initiating biologic therapy and for patients still on biologic therapy after 1 year. Also, to quantify and compare the use of topical therapy among patients still on biologic therapy after 1 year. Methods: This nationwide cohort study compared characteristics of patients prescribed adalimumab, etanercept, infliximab, secukinumab or ustekinumab for treatment of psoriasis by using data from the Danish registries. Results: In the ustekinumab group, patients were younger and fewer had psoriatic arthritis. Patients treated with secukinumab and ustekinumab were less frequently co-treated with conventional systemics and topical therapy. All other patient characteristics such as sex, smoking and comorbidities other than psoriatic arthritis were similar across the biologic cohorts. Conclusion: These results highlight the need to better understand which factors to consider when prescribing biologics to patients with psoriasis.

Indexed as

biological productscomorbidityepidemiologypsoriasisregistries

Identifiers

PMID39301091
PMCPMC11361497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.